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INTERSTITIAL LUNG DISEASE
Short course dexamethasone treatment following injury
inhibits bleomycin induced fibrosis in rats
W A Dik, R J McAnulty, M A Versnel, B A E Naber, L J I Zimmermann, G J Laurent,
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Background: Corticosteroids are routinely used in patients with pulmonary fibrosis. The timing for ini-
tiation of treatment is likely to be crucial for corticosteroids to exert an antifibrotic effect. Experimental
studies in animals have examined the effect of corticosteroid treatment starting before or at the time of
lung injury. However, this is not representative of the human condition as treatment only begins after
disease has been established. We examined the effect of a short course corticosteroid treatment start-
ing 3 days after bleomycin induced lung injury on the development of pulmonary fibrosis.
Methods: Bleomycin (1.5 mg/kg) was instilled intratracheally into rats to induce pulmonary fibrosis.
The effect of a 3-day course of dexamethasone (0.5 mg/kg) initiated 3 days after bleomycin induced
lung injury on cell proliferation and collagen deposition was examined by analysing bronchoalveolar
lavage (BAL) fluid and lung tissue.
Results: Treating bleomycin exposed animals after injury with dexamethasone for 3 days inhibited
lung collagen deposition compared with animals exposed to bleomycin without dexamethasone treat-
ment (15.2 (2.2) mg collagen/lung v 22.5 (2.1) mg/lung; p<0.05). Dexamethasone treatment
reduced pulmonary parenchymal cell proliferation in bleomycin exposed rats but did not influence BAL
fluid mitogenic activity for lung fibroblasts or alter the BAL fluid levels of the fibrogenic mediators trans-
forming growth factor-β1, platelet derived growth factor-AB, and thrombin.
Conclusions: A 3 day course of dexamethasone treatment initiated 3 days after bleomycin induced
lung injury reduces lung cell proliferation and collagen deposition by mechanisms other than through
reduction of transforming growth factor-β1, platelet derived growth factor-AB, and thrombin levels in
BAL fluid. We propose that an early short course treatment with dexamethasone may be useful in inhib-
iting pulmonary fibrosis.
Pulmonary fibrosis is the end stage of a heterogeneousgroup of disorders of known and unknown aetiology.Despite the wide variety of insults associated with this
condition—such as bacterial infection, inhalation of organic
and inorganic dusts, radiation, drugs, and trauma—the
mechanisms involved appear largely the same.1 It is assumed
that, in response to injury, inflammatory cells enter the lung
and, together with resident lung cells, release mediators that
stimulate fibroblast proliferation and collagen deposition
within the lung interstitium. In addition to this, mediators
influencing fibroblast proliferative activity may also originate
from the blood.1 A host of mediators has been implicated in
the pathogenesis of pulmonary fibrosis because they fit three
basic criteria: (1) they stimulate fibroblast replication or
procollagen synthesis; (2) the gene expression and protein
production of the mediator is increased in the lungs of
patients with pulmonary fibrosis; and (3) inhibitors of the
mediator function attenuate fibrosis in animal models of the
disease.2 Mediators which fit these criteria include platelet
derived growth factor (PDGF), transforming growth factor-β1
(TGF-β1), insulin like growth factor-1, endothelin-1, fibro-
nectin, and thrombin.1 3–9
The classical pathogenetic model for acute respiratory
distress syndrome (ARDS) suggests that epithelial and
endothelial damage results in an inflammatory phase that is
followed by a fibroproliferative phase which, if excessive,
results in established fibrosis. The current hypothesis,
however, is that fibroproliferation occurs in parallel with
inflammation.10 We have recently shown that fibroprolifera-
tion is indeed an early response to lung injury in ARDS and
may therefore be an important therapeutic target.11 Treatment
of ARDS with immunosuppressive corticosteroids was re-
ported to be more effective in inhibiting fibrosis development
when administered early in the fibroproliferative phase—that
is, before dense acellular fibrosis with deranged alveolar
architecture occurs. This response to treatment was found to
be associated with pulmonary improvement and a decrease in
the N-terminal propeptides of collagen types I and III in
plasma and bronchoalveolar lavage (BAL) fluid.12 13 These
findings clearly show that the time point at which cortico-
steroid treatment is initiated is crucial for exerting its
antifibrotic effect.
Neonatal respiratory distress syndrome has pathophysio-
logical features comparable to ARDS and can progress towards
bronchopulmonary dysplasia (BPD). The progression towards
BPD is associated with the development of fibrosis.14 Interest-
ingly, short course treatment with the corticosteroid dexam-
ethasone started 12–48 hours after birth in infants with neo-
natal respiratory distress syndrome increased survival without
BPD and reduced the requirement for subsequent late dexam-
ethasone treatment.15 16 This suggests that such a short course
of corticosteroid treatment initiated early after injury is able to
prevent lung fibrosis, but this has not been studied directly. If
short early treatment with dexamethasone indeed prevents
the development of fibrosis, it may be of clinical importance in
the treatment of patients at risk of developing pulmonary
fibrosis.
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Intratracheal instillation of the antitumour agent bleomy-
cin is the most commonly used animal model for pulmonary
fibrosis. This model is characterised by an early predominantly
neutrophilic inflammatory response, increased fibroblast pro-
liferation, and enhanced collagen deposition due to increased
collagen synthesis and decreased collagen degradation.17 18 In
addition, it has been shown that fibroproliferative activity
coexists with inflammation, and that the major proliferative
phase occurs during the first week after bleomycin induced
injury.19 20 Previous studies using prolonged administration of
corticosteroids such as methylprednisolone or dexamethasone
initiated before or simultaneously with bleomycin reduced
pulmonary inflammation, lung injury, and collagen deposition
in this model.21–23 However, as anti-inflammatory treatment
usually starts after lung injury has occurred, the clinical
relevance of starting treatment in animals before or at the
time of injury is questionable.
A study was undertaken to determine whether a 3 day
course of dexamethasone treatment (0.5 mg/kg body weight)
initiated 3 days after the induction of lung injury with
bleomycin affected collagen deposition and cell proliferation
and modulated the expression profile of the profibrotic
mediators TGF-β1, PDGF-AB, and thrombin in BAL fluid.
METHODS
Corticosteroid treatment in the bleomycin model
Male Lewis rats were intratracheally injected with bleomycin
disulphate (1.5 mg/kg body weight in 0.3 ml saline; Kyowa
Hakko, Slough, UK) as described previously.6 After 3 days the
animals were given a daily intraperitoneal injection of
dexamethasone sodium phosphate (0.5 mg/kg body weight in
0.5 ml saline; Sigma, St Louis, MO, USA) or saline for 3 days.
Groups of six rats were killed 3, 7, and 14 days after bleomycin
or saline instillation and their lungs were lavaged three times
with 4 ml saline. Total and differential cell counts were
performed and the BAL fluid was aliquoted and stored at
–80°C. The lungs were removed, blotted dry, and snap frozen in
liquid nitrogen. The lung collagen content and BAL fluid
mitogenic activity and growth factor levels were measured for
all groups.
For examination of cell proliferation, groups of three
animals were killed 3 and 5 days after bleomycin or saline
injection with and without dexamethasone treatment. Ani-
mals were injected intraperitoneally with bromodeoxyuridine
(BrdU; 15 µg/g body weight in 0.3 ml saline; Sigma) 1 hour
before killing, and the lungs were removed and processed for
immunohistochemical analysis as previously described.6 Par-
affin sections (5 µm) were stained using a BrdU Staining Kit
(ZYMED Laboratories Inc; South San Francisco, CA, USA)
according to the manufacturer’s instructions. The number of
BrdU positive cells was determined by light microscopy in 10
high power fields of lung tissue (400× magnification per
section). Institutional approval was obtained to perform these
animal studies.
Collagen measurement
Frozen powdered lung samples were hydrolysed in 2 ml of 6M
HCl at 110°C for 16 hours and the hydroxyproline content of
the proteins was measured.6 The amount of collagen in total
lung tissue was calculated assuming that lung collagen
contains 12.2% w/w hydroxyproline,24 and expressed as mg
collagen/lung.
Fibroblast proliferation assay
Human fetal lung fibroblasts (HFL-1) were seeded at 6 × 103
cells/well into 96-well plates in 50 µl Dulbecco’s modified
Eagle’s medium (DMEM; Gibco, Renfrewshire, UK) supple-
mented with 0.4% normal calf serum (NCS), L-glutamine, and
antibiotics and allowed to adhere for 24 hours. Thereafter,
50 µl of a 1/4 dilution of BAL fluid in DMEM/0.4% NCS was
added (six replicates per BAL fluid sample, yielding a 1/8 dilu-
tion of BAL fluid) and proliferation assessed after 48 hours
using a methylene blue colorimetric assay.25
Measurement of growth factors in BAL fluid
Total protein in BAL fluids was measured using a Bradford
based reagent (Bio-Rad;München, Germany). PDGF and total
TGF-β1 (latent and active TGF-β1) were measured using an
enzyme linked immunosorbent assay (ELISA; R&D Systems,
Abingdon, UK and Promega;Madison,WI, USA, respectively).
Thrombin activity was measured using a colorimetric assay
based on the conversion of a thrombin specific substrate (Tos-
Gly-Pro-Arg-pNA (Sigma)26) in the presence of BAL fluid with
and without the thrombin inhibitor PPACK (Bachem; Buben-
dorf, Switzerland) as described previously.27
Statistical analyses
The results are presented as mean (SE) values. Data between
groups were compared using the unpaired Student’s t test. A p
value of <0.05 was considered to be statistically significant.
RESULTS
Animal weights
Rats injected with bleomycin lost weight during the first 3
days after treatment but gained weight thereafter. Rats treated
with bleomycin and receiving dexamethasone continued to
lose weight during the 3 days of dexamethasone administra-
tion and started to gain weight again when dexamethasone
was stopped. Control animals receiving dexamethasone also
lost weight during treatment and started to gain weight again
when dexamethasone administration was stopped.
BAL fluid total and differential cell counts
For all animals, recovery of lavage fluid was 83.9 (0.7)% of the
used lavage volume. Recoveries did not differ between
treatment groups or between the examined time points. Table
1 shows the total leucocyte counts and composition of the cell
population in BAL fluid from the different groups at the
different time points examined. Three days after bleomycin
the total number of cells in the BAL fluid was significantly
increased compared with the control group. Furthermore, the
percentage of neutrophils was significantly higher and the
percentage of macrophages significantly lower than in the
control animals. At day 14 the total number of cells was still
higher in bleomycin treated animals, but the proportion of cell
types comprising the BAL cell population was comparable
with controls. There was a trend towards decreased cell num-
bers in the BAL fluid of dexamethasone treated animals com-
pared with controls at days 7 and 14, but these changes were
not statistically significant. However, there was a significantly
lower percentage of macrophages at days 7 and 14 following
bleomycin and dexamethasone treatment compared with
control animals, while the percentage of lymphocytes at day
14 was higher than in the control group.
Collagen measurement
Figure 1 shows the changes in total lung collagen 3, 7 and 14
days after instillation of bleomycin, with and without
dexamethasone treatment. Bleomycin had no effect on lung
collagen content at day 3. At day 7 the collagen content was
significantly increased in the bleomycin group given saline
(BLM) compared with the bleomycin group given dexametha-
sone (BLMdex) (14.2 (1.6) mg/lung v 9.7 (0.7) mg/lung;
p<0.05). The collagen content continued to increase in the
BLM group and by day14 was double that of the controls (22.5
(2.1) mg v 11.2 (1.1) mg; p<0.05). The lung collagen content
in the BLMdex group did not increase compared with control
animals treated (CTRLdex) or untreated (CTRL) with
dexamethasone at either 7 or 14 days. Animals in the BLMdex
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group had significantly reduced lung collagen at day 14 com-
pared with the BLM group (15.2 (2.2) mg v 22.5 (2.1) mg;
p<0.05). There was no significant change in total lung colla-
gen in control animals at any of the times examined.
Treatment of control animals with dexamethasone did not
influence the total lung collagen content at any time point.
BAL fluid induced fibroblast proliferation
Figure 2 shows the mitogenic effect of BAL fluid from animals
in each group on fibroblast proliferation over 48 hours. There
was a significant increase in BAL fluid induced fibroblast pro-
liferation at day 3 in animals exposed to bleomycin compared
with saline treated animals (28.4 (1.8)% proliferation above
medium control v 5.7 (1.4)%; p<0.05). No differences were
observed between bleomycin treated and control animals at
days 7 and 14. Treatment with dexamethasone did not signifi-
cantly influence the mitogenic activity of BAL fluid in bleomy-
cin treated animals at days 7 and 14. At day 7 the BAL fluid
from control animals exposed to dexamethasone had signifi-
cantly less mitogenic activity than bleomycin exposed animals
treated with dexamethasone (20.2 (4.9)% proliferation for
BLMdex compared with 3.0 (4.6)% for CTRLdex; p<0.05). No
significant change in BAL fluid mitogenic activity was
observed for dexamethasone treated and untreated controls at
any of the times examined.
Measurement of growth factors in BAL fluid
Total protein levels were significantly increased 3 days after
instillation of bleomycin (631.1 (56.4) µg/ml BAL fluid) com-
pared with controls (118.8 (47.6) µg/ml; p<0.05). Thereafter,
total protein levels declined in bleomycin treated animals but
were still significantly increased compared with controls at
day 14 (158.5 (26.7) µg/ml v 78.1 (12.3) ml; p<0.05).
Treatment with dexamethasone did not influence BAL fluid
total protein levels in bleomycin treated or control animals.
There was no significant change in BAL fluid total protein lev-
els in controls at any of the times examined (fig 3A).
Total TGF-β1 levels in BAL fluid were significantly increased
at day 3 after bleomycin treatment (616.4 (165.9) pg/ml BAL
fluid) compared with controls (98.9 (27.9) pg/ml; p<0.05).
TGF-β1 levels declined 7 days after bleomycin but were still
higher than in controls (194.6 (48.0) pg/ml v 46.1 (12) pg/ml;
p<0.05). At day 14 after bleomycin treatment TGF-β1 levels
were still significantly increased (230.6 (177.7) pg/ml) com-
pared with controls (24.9 (7.6) pg/ml BAL; p<0.05). Treat-
ment of bleomycin exposed and control animals with dexam-
ethasone did not influence TGF-β1 levels in BAL fluid at any of
the times examined. There was no significant change in
TGF-β1 levels in controls at any of the times examined (fig 3B).
PDGF-AB levels in BAL fluid were significantly increased at
day 3 after bleomycin (209.9 (25.8) pg/ml) compared with
controls (90 (6.2) pg/ml; p<0.05), and remained raised at
relatively constant levels during the study period. Treatment of
bleomycin exposed and control animals with dexamethasone
did not influence PDGF-AB levels in BAL fluid at any of the
times examined. There was no significant change in PDGF-AB
levels for controls at any of the times examined (fig 3C).
Thrombin activity in BAL fluid was significantly increased
at day 3 after exposure to bleomycin (0.6 (0.07) OD units at
405 nm) compared with controls 0.1 (0.03) OD units at
405 nm; p<0.05). Thereafter, thrombin activity gradually
declined in BAL fluid of bleomycin treated animals but
remained significantly raised at all times examined compared
with controls (fig 3D). Treatment of bleomycin exposed and
control animals with dexamethasone did not influence
thrombin activity in BAL fluid at any of the times examined.
In control animals BAL fluid thrombin activity was higher at
day 3 than in controls at days 7 and 14 (fig 3D).
Table 1 Total and differential BAL fluid cell counts for the four groups of animals at days 3, 7 and 14
Day 3 Day 7 Day 14
CTRL BLM CTRL CTRLdex BLM BLMdex CTRL CTRLdex BLM BLMdex
No of cells/ml BAL
fluid (×104)
5.2 (1.0) 26.8 (5.7)* 10.0 (3.0) 5.5 (1.3) 10.0 (3.8) 7.3 (2.8) 5.8 (1.3) 4.8 (0.6) 10.4 (2.0)* 7.2 (1.4)
% neutrophils 4.1 (2.9) 47.0 (5.2)* 1.6 (0.7) 1.0 (0.4) 24.4 (8.6) 15.7 (7.4) 0.7 (0.3) 1.0 (0.2) 2.0 (1.0) 5.6 (2.1)
% macrophages 95.1 (2.9) 46.9 (6.8)* 98.3 (0.6) 98.3 (0.5) 73.2 (9.3) 81.1 (8.3)* 99.0 (0.4) 98.9 (0.3) 97.1 (1.1) 93.6 (2.1)*
% lymphocytes 0.9 (0.3) 6.1 (1.9) 0.1 (0.1) 0.7 (0.2) 2.4 (0.9) 3.1 (1.1) 0.3 (0.1) 0.1 (0.1) 1.0 (0.5) 0.9 (0.3)*
CTRL=control with saline; BLM=bleomycin with saline; CTRLdex=control with dexamethasone; BLMdex=bleomycin with dexamethasone.
*p<0.05 (Student’s t test) v appropriate control group.
All groups consisted of six animals except CTRL at day 7 (n=3) and CTRLdex at day 7 (n=5).
Figure 1 Change in lung collagen content at various times
following instillation of bleomycin. The collagen content was
measured 3–14 days after intratracheal instillation of bleomycin or
saline, with and without a 3 day course of intraperitoneal
dexamethasone. Each value represents the mean (SE). Four different
treatment groups were studied: (1) bleomycin with saline (BLM); (2)
bleomycin with dexamethasone (BLMdex); (3) control with saline
(CTRL); and (4) control with dexamethasone (CTRLdex). All groups
consisted of six animals except the CTRL group on day 7 (n=3) and
the CTRLdex group on day 7 (n=5).
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Figure 2 Effect of a 1/8 dilution of BAL fluid on fibroblast
proliferation 3–14 days after intratracheal instillation of bleomycin or
saline with and without a 3 day course of dexamethasone.
Proliferation was expressed as the percentage change in mean
absorbance above that for cells exposed to DMEM/0.4% NCS
alone. Each value represents the mean (SE).
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Cell proliferation by BrdU incorporation
Very few cells were proliferating in the lung tissue of control
animals as assessed by BrdU immunoreactivity, with staining
limited to a few cells whose appearance and location were
consistent with that of alveolar type II epithelial cells (fig 4A).
In animals exposed to bleomycin, increased numbers of BrdU
positive alveolar type II epithelial resembling cells and
interstitial cells were clearly evident both in bleomycin injured
areas (fig 4B–D) and in normal areas of lung parenchyma at
all times examined. Treatment of bleomycin exposed animals
with dexamethasone significantly reduced the number of
BrdU positive cells, both in areas of bleomycin induced injury
and normal lung parenchyma (fig 5).
DISCUSSION
Previous studies have shown that prolonged administration of
corticosteroids, initiated before or at the same time as
bleomycin administration, inhibited the development of lung
fibrosis in rats.21–23 Although an important finding, its clinical
relevance is questionable as anti-inflammatory treatment is
always given after lung damage has occurred. In our study the
corticosteroid concentration used was much lower than in
previous studies,21–23 treatment was initiated after bleomycin
induced lung injury, and it was only administered for a short
time. We clearly show that a 3 day course of dexamethasone
treatment (0.5 mg/kg/day) started 3 days after bleomycin
induced lung injury causes reduced collagen deposition in the
lungs of rats 14 days after exposure to bleomycin. From these
data we cannot exclude the possibility that dexamethasone
delays rather than inhibits the fibrotic response. However, as
bleomycin induces acute inflammation, it is unlikely that a
further inflammatory response will be seen after 7 days, espe-
cially when animals have been treated with dexamethasone.
Indeed, the lavage cell counts of animals treated with bleomy-
cin and dexamethasone, although not significantly different,
tended to be lower than those in animals treated with
bleomycin alone at 7 and 14 days. As there was no increase in
collagen deposition compared with controls at day 14 in
animals exposed to bleomycin and treated with dexametha-
sone, it is unlikely that there will be a significant change at
later time points, which suggests that our data represent sup-
pression rather than a delay of fibrogenesis.
The current theory on the pathogenesis of pulmonary
fibrosis is based on the hypothesis that mediators released by
inflammatory cells and resident lung cells as well as blood
borne mediators induce fibroblasts to proliferate and/or to
produce excess collagen.1 In agreement with previous
studies,17 19 we observed a significant increase in the number of
inflammatory cells after bleomycin treatment which de-
creased after 3 days. We observed no significant difference in
the inflammatory cell population between dexamethasone
treated and untreated bleomycin exposed animals. This may
account for the fact that no differences were observed in BAL
fluid levels of TGF-β1 and PDGF-AB between these groups of
animals.
TGF-β1 is a potent stimulator of collagen synthesis by
fibroblasts,28 and TGF-β1 mRNA expression is increased before
increases occur in type I and type III procollagen mRNAs in
bleomycin induced lung fibrosis.29 Different approaches to
inhibit TGF-β have been successfully used to prevent bleomy-
cin induced pulmonary fibrosis. Neutralising TGF-β antibod-
ies, soluble TGF-β type II receptors, and decorin are all able to
inhibit TGF-β1 activity and reduce collagen accumulation after
bleomycin treatment.30–32 In our study we detected increased
levels of TGF-β1 in BAL fluid after bleomycin, comparable with
levels reported previously.32 33 Dexamethasone did not down-
regulate TGF-β1 levels in BAL fluid at any of the times exam-
ined after bleomycin treatment. Although we did not study
protein expression by BAL fluid cells, it is likely that alveolar
macrophages substantially contributed to the TGF-β1 levels in
BAL fluid as these cells have been shown to express and
secrete TGF-β after exposure to bleomycin.34 35 Furthermore,
TGF-β1 levels were reduced seven days after bleomycin
treatment, which coincided with a reduction in inflammatory
cell numbers. Our observation that dexamethasone was
Figure 3 Changes in BAL fluid levels of (A) total protein, (B) total transforming growth factor (TGF)-β1, (C) platelet derived growth factor
(PDGF)-AB, and (D) thrombin 3–14 days after instillation of bleomycin or saline with and without a 3 day course of dexamethasone. The
sensitivity of the assays was 25 pg/ml and 8.4 pg/ml for TGF-β1 and PDGF-AB, respectively. Thrombin activity is expressed as optical density
at 405 nm (OD405 nm), determined as the difference in OD measured at 24 hours between the sample with and without PPACK. Each value
represents the mean (SE). Four different treatment groups were studied: (1) bleomycin with saline (BLM); (2) bleomycin with dexamethasone
(BLMdex); (3) control with saline (CTRL); and (4) control with dexamethasone (CTRLdex). All groups consisted of six animals except CTRL on day
7 (n=3) and CTRLdex on day 7 (n=5).
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unable to reduce TGF-β1 levels in vivo is supported by in vitro
findings that dexamethasone did not reduce TGF-β secretion
by alveolar macrophages which had previously been activated
in vivo by bleomycin.35
BAL fluid from bleomycin treated animals has been shown
to contain mitogenic activity for lung fibroblasts, due partly to
PDGF and thrombin.19 20 In addition, in vivo inhibition of
thrombin and PDGF activity reduced bleomycin induced pul-
monary fibrosis in rats.3 9 The mitogenic activity of BAL fluid
was significantly increased 3 days after bleomycin treatment
and returned to control levels by day 7, which supports previ-
ously reported findings.19 Treatment with dexamethasone had
no effect on the mitogenic activity of BAL fluid in animals
exposed to bleomycin. Both PDGF-AB levels and thrombin
activity were significantly increased at day 3 after bleomycin,
and presumably contributed to BAL fluid mitogenicity at that
time point. Thrombin activity decreased gradually thereafter
but remained significantly higher than in controls. The
PDGF-AB levels remained increased at a relatively constant
level during the whole study period, suggesting that the main
source of PDGF was not inflammatory cells but was more
likely to be resident cells. Thrombin activity and PDGF-AB
levels in BAL fluid were not modulated by dexamethasone
treatment of animals exposed to bleomycin. These data
suggest that, although a 3 day course of dexamethasone is able
to inhibit bleomycin induced pulmonary fibrosis in rats, this is
not achieved by reducing levels of the fibrogenic mediators
TGF-β1, PDGF-AB, or thrombin in BAL fluid.
We chose to examine TGF-β1, PDGF, and thrombin levels as
these are among the most important fibrogenic mediators
known to play a role in the pathophysiology of pulmonary
fibrosis.1 3 4 8 9 34 However, other mediators such as
endothelin-1, insulin-like growth factor-1, interleukin (IL)-
11, IL-13, and members of the fibroblast and epidermal
growth factor families may also be involved.6 36–38 From our
study we cannot exclude the possibility that treatment with
dexamethasone exerts its antifibrotic effect via mechanisms
involving mediators other than TGF-β1, PDGF, and thrombin.
We also cannot rule out the possibility that dexamethasone
treatment affects the parenchymal levels or activity of these
growth factors. For instance, fibroblasts have also been identi-
fied as a source of TGF-β1 in pulmonary fibrosis,39 and it has
been shown that dexamethasone reduces TGF-β1 mRNA and
TGF-β secretion by lung fibroblasts.40 In addition, dexametha-
sone is known to reduce collagen synthesis and steady state
levels of procollagen mRNA by lung fibroblasts.41 The dexa-
methasone regimen used in our study may therefore have
reduced parenchymal TGF-β1 expression by fibroblasts with
Figure 4 BrdU immunoreactive cells in (A) control lung tissue 3 days after saline instillation, (B) 3 days after bleomycin instillation, (C) 5 days
after bleomycin instillation without dexamethasone treatment, and (D) 5 days after bleomycin instillation with dexamethasone. Magnification
×400.
Figure 5 Number of BrdU immunoreactive cells presented as mean
number of positive cells of 10 high power fields at 400×
magnification in (A) areas of normal appearance lung tissue 3 and 5
days after bleomycin or saline instillation with and without
dexamethasone treatment and (B) bleomycin injured lung tissue 3
days after bleomycin instillation and 5 days after bleomycin
instillation with and without dexamethasone treatment.
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subsequent decreased autocrine stimulation of collagen
synthesis. Alternatively, stimulation of fibroblasts with dex-
amethasone stimulates the production of the proteoglycan
decorin that binds and inactivates TGF-β.42 Transient expres-
sion of decorin in the lungs from bleomycin treated animals
has been shown to reduce pulmonary fibrosis without reduc-
ing total TGF-β1 levels in BAL fluid.32 It is therefore possible
that the dexamethasone treatment in our study reduced
parenchymal TGF-β1 activity by increasing the decorin levels
in the lung with decreased collagen deposition as a
consequence.
Intratracheal instillation of bleomycin resulted in BrdU
incorporation into cells resembling alveolar type II epithelial
cells in areas of normal lung architecture and in bleomycin
injured areas, indicating an increase in the number of
proliferating cells. This finding supports previous studies and
shows that active epithelial proliferation contributes to repair
of the injured epithelial surface within the first few days of
injury.43 44 In this study we examined cell proliferation in lung
tissue from bleomycin treated and control animals after 3 and
5 days. Later time points were not examined as previous stud-
ies have shown that maximal cell proliferation occurs within
the first week after bleomycin exposure.20 44 Treatment with
dexamethasone reduced the number of BrdU stained cells in
both injured and normal areas of the lung parenchyma in
bleomycin treated animals. This suggests that dexamethasone
either prevents or delays cell proliferation. Apoptosis is also
known to play a key role in the development of bleomycin
induced pulmonary fibrosis.45 In addition, it has been reported
that prolonged administration of a high dose of methylpred-
nisolone (100 mg/kg/day) suppressed bronchial and alveolar
epithelial apoptosis and reduced evidence of histological
fibrosis induced by bleomycin.46 Dexamethasone may there-
fore have also reduced epithelial cell apoptosis which, together
with reduced fibroblast proliferation, prevented or delayed the
development of fibrosis. However, TUNEL staining for
apoptotic cells on lung sections from the current study were
inconclusive (data not shown).
This study is the first to show that a 3 day course of
treatment with dexamethasone, started after initiation of
bleomycin induced fibrosis and given during the major prolif-
erative phase, is able to reduce excessive pulmonary collagen
deposition in rats. The observed effect of dexamethasone is
established without a reduction in inflammatory cell numbers
or the fibrogenic mediators TGF-β1, PDGF-AB, and thrombin
in the alveolar space. We speculate that the antifibrotic effect
of dexamethasone is mediated via other pathways which may
include reduced or delayed cell proliferation, decreased
epithelial apoptosis, or inhibition of tissue profibrotic media-
tor activity. Our findings are of important clinical relevance as
corticosteroid treatment is the mainstay of treatment in
patients with pulmonary fibrosis, ARDS, and neonatal
respiratory distress syndrome, and the timing of initiating
treatment appears to be crucial for its antifibrotic effects.
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Radiofrequency ablation of lung cancer
m Herrera LJ, Fernando HC, Perry Y, et al. Radiofrequency ablation of pulmonary malignant tumors in nonsurgical
candidates. J Thorac Cardiovasc Surg 2003;125:929–37
Lung cancer is the most common cause of cancer related death in the USA. Surgical resec-tion is the treatment of choice in non-small cell lung cancer (NSCLC).Many patients havepoor pulmonary function or other medical co-morbidities and are not suitable for
resection. Such patients are offered alternative treatments such as radiotherapy and chemo-
therapy, with poorer long term survival. Radiofrequency ablation (RFA) is a thermal energy
delivery system that applies alternating current through a needle electrode into the tumour.
It has been used for treating unresectable liver tumours.
In this pilot study at the University of Pittsburgh, 33 tumour nodules in 18 patients were
treated with RFA. Five of the patients had NSCLC (stage I (n=3), stage IV (n=2)) and 13 had
pulmonary metastases from an extrathoracic malignancy (sarcoma, colon,melanoma, renal).
Two of the five patients with NSCLC had recurrence of disease after thoracotomy and resec-
tion. All patients underwent a chest CT scan before and after RFA. Patients were followed up
at 1 and 3 month intervals with a CT scan of the chest. At a median follow up of 6 months
(range 1–10) four of the five patients with NSCLC were alive; the other patient died at the age
of 95 years without evidence of disease progression. Seven of the 13 patients with pulmonary
metastases were alive at a median follow up of 4 months. The response rate was better for
lesions less than 5 cm in diameter.
Although RFA will not replace surgical resection as the treatment of choice for NSCLC, it
may offer better survival in selected patients and additional trials are needed to determine its
role.
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